Denali Therapeutics (STU:4DN) Scaled Net Operating Assets: 0.12 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:4DN Denali Therapeutics Inc STU:4DN
39 GF Score
Price €21.91
! 6 Warning Signs
View Full Analysis

What is Denali Therapeutics Scaled Net Operating Assets?

Denali Therapeutics STU:4DN +4.78% 39 Scaled Net Operating Assets is 0.12 as of Jun. 2026. GuruFocus rates STU:4DN with a GF Score™ of 39/100. The stock has 6 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Denali Therapeutics's operating assets for the quarter that ended in Jun. 2026 was €388.42 Mil. Denali Therapeutics's operating liabilities for the quarter that ended in Jun. 2026 was €252.21 Mil. Denali Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was €1,095.11 Mil. Therefore, Denali Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2026 was 0.12.


Denali Therapeutics Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Denali Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Denali Therapeutics Scaled Net Operating Assets Chart

Denali Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 -0.18 0.03 0.40 0.12

Denali Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.10 0.17 -0.02 0.12

STU:4DN vs RCUS, ALMS, ELVN: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Denali Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Denali Therapeutics Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Denali Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Denali Therapeutics's Scaled Net Operating Assets falls into.


STU:4DN
39GF Score
Denali Therapeutics Inc STU:4DN
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Denali Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Denali Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(236.536-80.564)/1312.342
=0.12

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=977.705 - 741.169
=236.536

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=111.953 - 23.237 - 8.152
=80.564

Denali Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Jun. 2026 )
=(Operating Assets (Q: Jun. 2026 )-Operating Liabilities (Q: Jun. 2026 ))/Total Assets (Q: Mar. 2026 )
=(388.416-252.214)/1095.11
=0.12

where

Operating Assets(Q: Jun. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1005.105 - 616.689
=388.416

Operating Liabilities(Q: Jun. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=280.17 - 19.119 - 8.837
=252.214

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.12 mean?
Denali Therapeutics (STU:4DN) has a Scaled Net Operating Assets of 0.12 as of Jun. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Denali Therapeutics and its competitors.
Is Denali Therapeutics' Scaled Net Operating Assets too high?
Denali Therapeutics' current Scaled Net Operating Assets is 0.12. Overall, Denali Therapeutics has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Denali Therapeutics' Scaled Net Operating Assets compare to RCUS and ALMS?
Denali Therapeutics' Scaled Net Operating Assets of 0.12 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Denali Therapeutics and its competitors. Denali Therapeutics's current Scaled Net Operating Assets is 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Denali Therapeutics stock overvalued right now?
Denali Therapeutics (STU:4DN) has a current Scaled Net Operating Assets of 0.12. The current Scaled Net Operating Assets is 0.12. Denali Therapeutics' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Denali Therapeutics (STU:4DN), the current Scaled Net Operating Assets is 0.12 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Denali Therapeutics Business Description

Other Exchanges DNLI:USAD2NL34:Brazil
Address 161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
39GF Score

Get the complete analysis for STU:4DN

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.91
Price